Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + RC148 in First-Line Non-Squamous NSCLC
NCT07874282Phase 2Not yet recruiting
- Sponsor
- RemeGen
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan, RC148 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by RemeGen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecanRC148
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07874282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874282.